FDA Finalizes Guidance on Ensuring Smooth Transfer of IRBs

Drug Industry Daily
A A
Institutional review boards (IRBs) that assume oversight of a clinical trial from another IRB should give drugmakers an opportunity to address any concerns the receiving IRB has with the study before it is terminated or suspended, the FDA says in a final guidance that makes only minor tweaks to the 2012 draft.

To View This Article:

Login

Subscribe To Drug Industry Daily